MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$3,004K
Net Income
-$20,421K
Net Profit Margin
-679.79%
EPS
-$1.18
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
3,004
19,635
860
12,475
Research and development
15,343
16,657
166,596
154,948
General and administrative
10,279
20,258
88,742
46,333
Total operating expenses
25,622
36,915
255,338
201,281
Loss from operations
-22,618
-17,280
-254,478
-188,806
Interest income
2,104
-
17,854
14,744
Other income (expense), net
328
-
-477
-380
Total other income (expense)
2,432
647
17,377
14,364
Net loss
-20,186
-16,633
-237,101
-174,442
Net unrealized gain on short-term investments
-235
-
807
-4
Foreign currency translation adjustment
-
-
-14
-5
Comprehensive loss
-20,421
-
-236,308
-174,451
Basic EPS
-1.18
-0.97
-1.534
-1.27
Diluted EPS
-1.18
-0.97
-1.534
-1.27
Basic Average Shares
17,106,000
17,105,643
154,091,000
137,895,000
Diluted Average Shares
17,106,000
17,105,643
154,091,000
137,895,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$20,421K
(87.10%↑ Y/Y)
Interest income
$2,104K
(-85.47%↓ Y/Y)
Other income
(expense), net
$328K
(150.38%↑ Y/Y)
Net loss
-$20,186K
(87.17%↑ Y/Y)
Net unrealized gain
on short-term...
-$235K
(78.32%↑ Y/Y)
Total other income
(expense)
$2,432K
(-82.41%↓ Y/Y)
Loss from operations
-$22,618K
(86.78%↑ Y/Y)
Collaboration revenue
$3,004K
(-21.91%↓ Y/Y)
Total operating
expenses
$25,622K
(-85.36%↓ Y/Y)
Research and development
$15,343K
(-88.89%↓ Y/Y)
General and
administrative
$10,279K
(-72.12%↓ Y/Y)
Buy us a coffee
Atrium Therapeutics, Inc. (RNA)
Atrium Therapeutics, Inc. (RNA)